RTP Mobile Logo
Select Publications

Daniel Catenacci, MD

Bang Y-J et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97. Abstract

Catenacci DVT et al. Margetuximab plus pembrolizumab for previously treated, HER2-positive GEA (CP-MGAH22-05): A single-arm, phase 1b-2 trial. Lancet Oncol 2020;21(8):1066-76. Abstract

Satoh T et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN — A randomized, phase III study. J Clin Oncol 2014;32(19):2039-49.  Abstract

Shitara K et al. Trastuzumab deruxtecan in previously treated HERx2-positive gastric cancer. N Engl J Med 2020;382(25):2419-30. Abstract

Shitara K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01). ASCO 2020;Abstract 4513.

Thuss-Patience PC et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 2017;18(5):640-53. Abstract

Yelena Y Janjigian, MD

Cristescu R et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21(5):449-56. Abstract

Janjigian YY et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial. Lancet Oncol 2020;21(6):821-31. Abstract

Janjigian YY et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov 2018;8(1):49-58. Abstract

Shitara K et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 2020;6(10):1571-80. Abstract

Smyth EC et al. Mismatch repair deficiency, microsatellite instability, and survival: An exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol 2017;3(9):1197-203. Abstract

Rutika Mehta, MD, MPH

Fuchs CS et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):420-35. Abstract

Shitara K et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 2018;392(10142):123-33. Abstract

Türeci O et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: The MONO study. Ann Oncol 2019;30(9):1487-95. Abstract

Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 2014;15(11):1224-35. Abstract

Yoshikawa T et al. Effect of first-line S-1 plus oxaliplatin with or without ramucirumab followed by paclitaxel plus ramucirumab on advanced gastric cancer in east Asia: The phase 2 RAINSTORM randomized clinical trial. JAMA Netw Open 2019;2(8):e198243. Abstract

Zev Wainberg, MD, MSc

Cho BC et al. Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study. ESMO 2019;Abstract LBA11.

Kato K et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. ESMO 2020;Abstract LBA8_PR.

Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. ESMO 2020;Abstract LBA9_PR.

Kojima T et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. ASCO Gastrointestinal Cancers Symposium 2019;Abstract 2.